JAN 29, 2010
Comprehensive Ophthalmology, Glaucoma
Patients on latanoprost monotherapy who required additional IOP lowering discontinued latanoprost and were randomized to bimatoprost 0.03% (?131 patients) or travoprost 0.004% (?135 patients). Overall, 22 percent of bimatoprost patients versus 12.1 percent of travoprost patients achieved at least an additional 15 percent reduction in diurnal IOP at one and three months follow-up. Rate of increased hyperaemia was low in patients switched to either bimatoprost or travoprost.